Mesoblast Files Director Interest Change & New Issue Announcement

Ticker: MEOBF · Form: 6-K · Filed: Apr 9, 2025 · CIK: 1345099

Mesoblast LTD 6-K Filing Summary
FieldDetail
CompanyMesoblast LTD (MEOBF)
Form Type6-K
Filed DateApr 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: disclosure, director-filing, new-issue

TL;DR

MESO files director interest change & new issue announcement with ASX.

AI Summary

On April 8, 2025, Mesoblast Limited filed a new issue announcement and a change of director's interest notice (Appendix 3Y) with the Australian Securities Exchange. This filing is part of their ongoing reporting requirements as a foreign private issuer.

Why It Matters

This filing provides transparency into potential changes in director holdings and new share issuances, which can signal management's confidence or strategic moves.

Risk Assessment

Risk Level: low — This is a routine disclosure filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What specific type of director's interest notice was filed?

A change of director's interest notice, specifically an Appendix 3Y, was filed.

What other announcement was filed along with the Appendix 3Y?

A new issue announcement was filed concurrently.

On what date were these announcements filed with the Australian Securities Exchange?

The announcements were filed on April 8, 2025.

What is Mesoblast Limited's primary business classification according to the filing?

Mesoblast Limited is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.

Is Mesoblast Limited required to file annual reports under Form 20-F or Form 40-F?

Yes, Mesoblast Limited indicates it files annual reports under Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 9, 2025 by Silviu Itescu regarding MESOBLAST LTD (MEOBF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing